Non-covalent btki pirtobrutinib shows promise as frontline therapy for CLL/SLL
Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms of overall response rate in the first head-to-head comparison with ibrutinib, a covalent BTK inhibitor. ...
Dec 8, 2025
0
5









